Document ID: chunk:federal_register_of_legislation:F2022L01120:reg:9
Version: federal_register_of_legislation:F2022L01120
Segment Type: reg
Provision Reference: reg 9
Character Range: 3108–5710

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting steatohepatitis or death from steatohepatitis with the circumstances of a person's relevant service:
(1)          having hypertension before the clinical onset of steatohepatitis;
(2)          having diabetes mellitus at the time of the clinical onset of steatohepatitis;
(3)          being obese at the time of the clinical onset of steatohepatitis;
Note: being obese is defined in the Schedule 1 – Dictionary.
(4)          having rapid weight loss causing protein-calorie malnutrition within the 18 months before the clinical onset of steatohepatitis;
Note: rapid weight loss is defined in the Schedule 1 – Dictionary.
(5)          undergoing jejunoileal bypass surgery before the clinical onset of steatohepatitis;
(6)          receiving total parenteral nutrition for at least 3 months within the 1 year before the clinical onset of steatohepatitis;
Note: total parenteral nutrition is defined in the Schedule 1 – Dictionary.
(7)          having dyslipidaemia at the time of the clinical onset of steatohepatitis;
Note: dyslipidaemia is defined in the Schedule 1 – Dictionary.
(8)          for males, consuming at least 55 kilograms of alcohol within any 5 year period before the clinical onset of steatohepatitis;
Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(9)          for females, consuming at least 30 kilograms of alcohol within any 5 year period before the clinical onset of steatohepatitis;
Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.
(10)      having hyperuricaemia at the time of the clinical onset of steatohepatitis;
Note: hyperuricaemia is defined in the Schedule 1 – Dictionary.
(11)      taking irinotecan for at least the 30 days before the clinical onset of steatohepatitis;
(12)      taking a drug specified in the Schedule 2 - Drugs of this Instrument, that cannot be ceased or substituted, for at least the 30 days before the clinical onset of steatohepatitis;
(13)      taking a drug that cannot be ceased or substituted and which is associated in the individual with:
(a)          the development of steatohepatitis within 30 days of first taking the drug; and
(b)          the redevelopment of steatohepatitis on rechallenge with the same drug;
(14)      inability to obtain appropriate clinical management for steatohepatitis.